Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASNDNYSEARCA:DBVNASDAQ:GRINASDAQ:NEPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$173.06-2.5%$158.95$111.09▼$183.00$10.83B0.37492,509 shs595,956 shsDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AGRIGRI Bio$1.38-3.5%$1.51$1.10▼$64.09$2.96M-1.68298,500 shs43,075 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-2.53%+5.92%+7.26%+18.75%+24.95%DBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%GRIGRI Bio-3.50%-0.72%-22.91%-78.96%-97.83%NEPTNeptune Wellness Solutions0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S3.3547 of 5 stars4.52.00.00.03.31.70.6DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AN/AN/AGRIGRI Bio2.8975 of 5 stars3.55.00.00.00.00.01.3NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$216.7325.24% UpsideDBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/AGRIGRI Bio 3.00Buy$22.001,494.20% UpsideNEPTNeptune Wellness Solutions 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GRI, NEPT, ASND, and DBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$196.00 ➝ $201.005/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.005/12/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.005/5/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.005/2/2025ASNDAscendis Pharma A/SRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.005/2/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.005/2/2025ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$181.00 ➝ $212.005/2/2025ASNDAscendis Pharma A/SEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$260.00 ➝ $280.004/16/2025ASNDAscendis Pharma A/SRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$205.004/14/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$168.00 ➝ $200.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$368.70M28.62N/AN/A($1.88) per share-92.05DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/A$5.22 per shareN/ANEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$6.28N/A721.08N/A-104.54%N/A-39.23%N/ADBVInvesco DB G10 Currency Harvest FundN/AN/A0.00∞N/AN/AN/AN/AN/AGRIGRI Bio-$13.04M-$11.56N/AN/AN/AN/A-289.05%-165.01%8/12/2025 (Estimated)NEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/ALatest GRI, NEPT, ASND, and DBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/A5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ADBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AGRIGRI Bio$1.91138.41%N/AN/A N/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.170.84DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AGRIGRI BioN/A3.103.10NEPTNeptune Wellness SolutionsN/A0.230.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ADBVInvesco DB G10 Currency Harvest Fund85.24%GRIGRI Bio33.95%NEPTNeptune Wellness Solutions14.44%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%DBVInvesco DB G10 Currency Harvest FundN/AGRIGRI Bio0.13%NEPTNeptune Wellness Solutions5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S64060.97 million36.41 millionOptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableGRIGRI Bio12.14 million8.92 millionNot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableGRI, NEPT, ASND, and DBV HeadlinesRecent News About These Companiest20 world cup 2020 teamsDecember 28, 2024 | bweducation.businessworld.inNeptune Wellness Solutions Inc. (NEPTF)November 27, 2024 | finance.yahoo.comThree Breakthrough Strategies To Revolutionize Pain Relief And WellnessNovember 7, 2024 | forbes.comThe Aesthetic Experience introduces AE WellnessNovember 7, 2024 | koin.comNeptune homeless camp down to 13 people as deadline to shut it down is nearly hereOctober 18, 2024 | app.comThe Next Era of Lenovo Neptune Water Cooling Arrives to Efficiently Power NVIDIA Blackwell Platform and AI at Every ScaleOctober 15, 2024 | valdostadailytimes.comOpen Letter to Dominican President Luis Abinader: Stop Deportations Now!October 12, 2024 | counterpunch.org2024 Wellness Olympia Results & Prize Money — Isabelle Nunes Wins 1st TitleOctober 12, 2024 | fitnessvolt.comKroger Wellness Festival canceled, products will go to people impacted by HeleneSeptember 28, 2024 | local12.comRestore Hyper Wellness and MECOTEC Announce Strategic Partnership in Cryotherapy SolutionsSeptember 24, 2024 | tmcnet.comCapitol Wellness Solutions opens new medical marijuana dispensary in Baton RougeSeptember 21, 2024 | yahoo.comCapitol Wellness Solutions opened a new medical marijuana dispensary, for the first time in LouisianaSeptember 21, 2024 | msn.comGiant space balloon ‘Spaceship Neptune-Excelsior’ completes 2nd test flight in TitusvilleSeptember 19, 2024 | clickorlando.comSpace Perspective's Spaceship Neptune capsule lifts off from ship on test flightSeptember 16, 2024 | floridatoday.comNeptune Beach, FL Weather ConditionsAugust 30, 2024 | wunderground.comHigh-tech wizardry and old-fashioned care will grow pot indoors at Neptune's GardenAugust 30, 2024 | app.comYour Daily Horoscope: Sunday, August 25, 2024August 25, 2024 | msn.comExploring Alternative Wellness Options for Stress Management & RelaxationAugust 25, 2024 | spacecoastdaily.comSunrise Total Mind Wellness closing its doors in New BraunfelsAugust 18, 2024 | herald-zeitung.comNeptune Medical raises $97M for surgical robotics, spins out Jupiter EndovascularAugust 16, 2024 | therobotreport.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s Watching3 Quality Stocks Trading Near 52-Week LowsBy Gabriel Osorio-Mazilli | May 30, 2025View 3 Quality Stocks Trading Near 52-Week LowsCAVA's Explosive Growth Makes It a Must-Watch StockBy Gabriel Osorio-Mazilli | May 19, 2025View CAVA's Explosive Growth Makes It a Must-Watch StockGRI, NEPT, ASND, and DBV Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$173.06 -4.49 (-2.53%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$173.02 -0.05 (-0.03%) As of 06/6/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Invesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.GRI Bio NASDAQ:GRI$1.38 -0.05 (-3.50%) As of 06/6/2025 04:00 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Neptune Wellness Solutions NASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
